Paris, November 2 (ots/PRNewswire) - The European School of Oncology (ESO) presented this year's joint winners of the ACE (Awarding Cancer Enlightenment) Reporter Award 2005 -- Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Nepszabadsag, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima -- with euro 5,000 each at an award ceremony held today at the European ...
Basel, Switzerland (ots/PRNewswire) - The news that the innovative new cancer drug Tarceva(R) (erlotinib) is now becoming available across the EU will provide a glimmer of hope to over 380,000 people in Europe this year who have received the devastating news that they have lung cancer. Not only has Tarceva demonstrated a striking survival benefit (42.5 per ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to treat or prevent human illnesses. E6020 is a chemically synthesized adjuvant that will be ...
Basel, Switzerland (ots/PRNewswire) - Following today's European approval of Boehringer Ingelheim's boosted protease inhibitor tipranavir (APTIVUS(R)), European patients now have the chance to benefit from the potent combination of the fusion inhibitor FUZEON (enfuvirtide) and boosted tipranavir in addition to ...
Amsterdam, The Netherlands (ots/PRNewswire) - - Valdoxan(R) (agomelatine) Provides Antidepressant Efficacy With the Additional Clinical Benefit of Sleep Improvement With no Effect on Daytime Vigilance The first melatonergic antidepressant, Valdoxan(R) (agomelatine), offers an innovative new approach to the treatment of depression. Valdoxan combines ...
Zurich (ots) - Prionics AG, the world leader in prion diagnostics and Pfizer Animal Health, the world's leading animal health company, agreed today that Prionics will acquire Pfizer Animal Health's diagnostic products. Terms were not disclosed. The product line includes tests for the detection of ...
Amsterdam, The Netherlands (ots/PRNewswire) - - New data also demonstrate SEROQUEL tolerability benefits versus other atypicals in schizophrenia and reinforce therapeutic potential in bipolar disorder Seroquel (quetiapine), olanzapine and risperidone are equally effective in patients experiencing first episode psychosis, according to data presented today ...
Alderley Park, England (ots/PRNewswire) - - For Health Professional Press and Non-UK Journalists Only Newly released top-line results from the BOLDER II (BipOLar DEpRession) study have underlined the potential for SEROQUEL (quetiapine fumarate) in the treatment of patients with major depressive episodes associated with bipolar disorder. In BOLDER ...
Berlin, Germany (ots/PRNewswire) - - For Healthcare Professional Journalists - Not for distribution to US media - Randomised, Placebo-Controlled Study Shows Discontinuation of Pramipexole Leads to Rapid Worsening of Symptoms - Two new, randomised, placebo-controlled studies presented this week at the ...
World Federation for Mental Health
Washington D.c. (ots/PRNewswire) - - Dr Benedetto Saraceno of WHO Will Keynote a Symposium to Mark 2005 WMHD in Washington D.C. The 13th World Mental Health Day (WMHD) will be celebrated today in many countries and this year examines the close relationship between mental and physical health across all ...
Cheshire, England (ots/PRNewswire) - ATTN: Health Press Most people with bipolar disorder believe that successful treatment would significantly improve their quality of life and that treatment satisfaction is achieved by efficacy and tolerability, according to final results from the large scale Thinking ...
London (ots/PRNewswire) - - Takeda's ACTOS(R) (pioglitazone HCl) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS(R) (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk ...
Dar Es Salaam, Tanzania (ots/PRNewswire) - - The Abbott Fund and the Government of Tanzania Dedicate New Hospital Facilities to Meet Long-Term Needs of Patients with HIV/AIDS and Other Diseases In a ceremony today, Abbott CEO Miles White joined Tanzanian President Benjamin William Mkapa in dedicating a ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. ("Isotechnika") and Atrium Medical Corporation ("Atrium") jointly announced today the signing of an exclusive worldwide licensing agreement for the use of TAFA93 and ISA247 specifically with drug eluting ...
Lyon, France et Swiftwater, Pennsylvanie (ots/PRNewswire) - - First Combination Vaccine Candidate in the U.S. Designed to Protect Infants and Young Children against Diphtheria, Tetanus, Pertussis, Polio, and Hib Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN), (NYSE: SNY), announced today the acceptance of a Biologics ...
Munich, Germany (ots/PRNewswire) - - Longer Storage Period Makes Platelets More Readily Available to European Transfusion Blood Centers European subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have received CE Mark Certification from TÜV Product Service GmbH extending the storage period ...
Durban, South Africa (ots/PRNewswire) - Trusted name Knorr is breaking new ground with Knorr Vie Shot, a naturally delicious drink bursting with fruits and vegetables. This fruit and vegetable "booster shot" is a direct response to consumers' health needs. With its focus on health and nutrition, Knorr runs an intensive consumer research program. Yet its ...
Brussels, Belgium (ots/PRNewswire) - Today UCB announced that the European Commission has approved the use of Keppra(R) (levetiracetam) in the European Union, as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in children from four to sixteen years of ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today the unblinded 12 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A Summary of the results is as follows: - The study met all primary and secondary efficacy endpoints determined at 12 weeks - Efficacy endpoints were achieved with minimal side effects - No clinically ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - - Influenza Vaccine Leader Takes New Step in Global Pandemic Preparedness LYON, France and SWIFTWATER, Pennsylvania, September 15 /PRNewswire/ -- Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an ...
Madrid (ots/PRNewswire) - - Further Steps in the Development of Aplidin(R) in Melanoma in First Line Therapy PharmaMar announces the initiation of a programme of combination studies with Aplidin(R) (plitidepsin), PharmaMar's novel marine-derived anti-tumour agent, originally isolated from the tunicate Aplidium albicans. Aplidin(R) in Combination with Dacarbazine (DTIC) The first study is a Phase I/II ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the participation level in its Canadian Phase III psoriasis extension trial for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to discontinue ...
Bayer Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.
West Haven, Connecticut, and Emeryville, California (ots/PRNewswire) - - European Trial to Provide Access to Sorafenib for Individuals with Advanced Renal Cell Carcinoma Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Marketing Authorization Application (MAA) has been submitted by Bayer to the European Medicines Agency (EMEA) in London for the ...
Newcastle, England (ots/PRNewswire) - The Procter & Gamble Company (NYSE:PG) has been selected as the "Nondurable Household Products" industry sector leader in the global Dow Jones Sustainability Index (DJSI) listings for the sixth year in a row. The Dow Jones Sustainability Indexes (DJSI), launched in 1999, are the first global indexes tracking the financial ...
Macclesfield, England (ots/PRNewswire) - Today, new guidelines from the prestigious St. Gallen 'International Consensus Conference on the Primary Therapy of Early Breast Cancer' were released ahead of publication on the Annals of Oncology website(1). For the first time, the St. Gallen consensus panel has ...
Geneva, Switzerland (ots/PRNewswire) - - Pharmacy Channel Capability - Important Step to Oral Care Leadership The Procter & Gamble Company (NYSE: PG) today announced that it has finalised the acquisition of Sanofi-aventis' global portfolio of trusted oral care brands for an undisclosed sum. "Fluocaril and Parogencyl, are leading pharmacy brands in Europe, Asia and Africa with an incredibly loyal consumer ...
New Brunswick, New Jersey (ots/PRNewswire) - Johnson & Johnson (NYSE: JNJ) has been notified that the European Commission has cleared its proposed acquisition of Guidant Corporation (NYSE: GDT). In conjunction with the Commission's clearance, Johnson & Johnson has agreed to divest its Cordis steerable guidewires business in Europe and the Guidant Endovascular ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile. The Canadian Phase III Psoriasis (SPIRIT) trial commenced on December 2, 2004 and includes a total of 453 patients with ...
Copenhagen, Denmark (ots/PRNewswire) - - International pharmaceutical Company Chooses MCI Private IP, IP Dedicated and Colocation to Link 58 Sites Across Europe, Asia and North and South America MCI, Inc. (Nasdaq: MCIP) today announced that the international pharmaceutical company H. Lundbeck A/S has selected MCI to link 58 of its site across Europe, Asia and North and South America using MCI Private IP, a ...
Rio De Janeiro, Brazil and Ingelheim, Germany (ots/PRNewswire) - - New Data Support its Use as Powerful Treatment Against HIV Drug Resistance RIO DE JANEIRO, Brazil and INGELHEIM, Germany, July 28 /PRNewswire/ -- Boehringer Ingelheim announced today that the CHMP (Committee for Medicinal Products for Human Use) in London has issued a positive opinion for tipranavir, a non-peptidic protease inhibitor, to ...